In contrast, serious adverse events observed in response to WEE1 inhibitors, which we and others have reported, are largely hematologic (e.g., anemia, neutropenia, and thrombocytopenia; ref. 53, 54). This evidence concerns the gene WEE1 and Thrombocytopenia.